The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - EFW Radiology
First-in-class microbial ecosystem therapeutics 4 (MET4) in metastatic solid cancer patients treated with immunotherapy: MET4-IO.
 
Daniel Vilarim Araujo
Honoraria - BMS Brazil; GlaxoSmithKline; Libbs
 
Marc Oliva Bernal
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Mirati Therapeutics
Travel, Accommodations, Expenses - MSD Oncology
Other Relationship - Merck
 
Tira Jing Ying Tan
Stock and Other Ownership Interests - Immunomedics
Honoraria - AstraZeneca; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Lilly
Research Funding - AstraZeneca (Inst); Bayer (Inst); Novartis (Inst); Odonate Therapeutics (Inst); Synthon (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Eisai
 
Alya Abbas Heirali
No Relationships to Disclose
 
Pierre H.H. Schneeberger
No Relationships to Disclose
 
Thiago Pimentel Muniz
No Relationships to Disclose
 
Bo Chen
No Relationships to Disclose
 
Lee-Anne Stayner
Travel, Accommodations, Expenses - Astellas Oncology
 
Kathy Xia
No Relationships to Disclose
 
Aaron Richard Hansen
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; GlaxoSmithKline/Novartis; Merck; Pfizer
Consulting or Advisory Role - Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; Merck; Novartis
Research Funding - Boehringer Ingelheim; Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Novartis (Inst); Roche/Genentech (Inst)
 
Ben X Wang
No Relationships to Disclose
 
David Hogg
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Merck Serono; Novartis; Roche
Research Funding - Bristol-Myers Squibb; Merck Serono
 
Kyla Cochrane
Employment - Nubiyota
 
Shawn Langer
Patents, Royalties, Other Intellectual Property - Nubiyota
 
Nissim Mashiach
Patents, Royalties, Other Intellectual Property - Nubiyota (Inst)
 
Wei Xu
No Relationships to Disclose
 
Lillian L. Siu
Leadership - Treadwell Therapeutics (I)
Stock and Other Ownership Interests - Agios (I)
Consulting or Advisory Role - Arvinas; AstraZeneca/MedImmune; GlaxoSmithKline; Loxo; Merck; Mirati Therapeutics; MorphoSys; Navire; Oncorus; Roche; Seagen; Symphogen; Treadwell Therapeutics; Voronoi Health Analytics
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVID Radiopharmaceuticals (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Intensity Therapeutics (Inst); Karyopharm Therapeutics (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Shattuck Labs (Inst); Symphogen (Inst)
 
Bryan Coburn
Research Funding - Nubiyota
 
Anna Spreafico
Honoraria - Janssen Oncology
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Novartis; Oncorus
Research Funding - Alkermes; Array BioPharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Janssen Oncology; Merck; Northern Biologics; Novartis; Replimune; Roche; Surface Oncology; Symphogen
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Idera; Janssen Oncology; Merck; Roche